Patents by Inventor Shuyuan Zhang

Shuyuan Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9428768
    Abstract: The present invention relates to improved methods for producing adenovirus compositions wherein host cells are grown in a bioreactor and purified by size partitioning purification to provide purified adenovirus compositions.
    Type: Grant
    Filed: October 28, 2009
    Date of Patent: August 30, 2016
    Assignee: Crucell Holland B.V.
    Inventors: Hai Pham, Shuyuan Zhang, Peter Clarke
  • Publication number: 20160119061
    Abstract: A burst-mode laser control circuit and related methods thereof are disclosed. Using an APC loop with an additional burst-mode control circuit, and a switch in series with a diode and in parallel with the laser, a continuous-mode laser driver is enabled to operate in burst-mode by turning the switch on or off via external logic. Burst-mode control manages the switch, and a bandwidth-select circuit using a high or low logic level input, wherein the laser is disabled and the bandwidth-select circuit enters a fast-track mode when the external logic signal has a first level. The laser provides regular optical signals, and the bandwidth-select circuit enters a slow-track mode, thereby enabling the APC loop to operate normally, when the external logic signal has a second level. In addition to a low cost and simple implementation, the control circuit and method provide lasers with a fast response capability using one or more externally-controlled switch circuits to meet demands of PON systems for burst-mode ONUs.
    Type: Application
    Filed: October 23, 2014
    Publication date: April 28, 2016
    Applicant: SOURCE PHOTONICS (CHENGDU) CO., LTD.
    Inventors: Xu JIANG, Yuan SONG, Shuyuan ZHANG, Yuanzhong XU
  • Patent number: 9325421
    Abstract: A burst-mode laser control circuit and related methods thereof are disclosed. Using an APC loop with an additional burst-mode control circuit, and a switch in series with a diode and in parallel with the laser, a continuous-mode laser driver is enabled to operate in burst-mode by turning the switch on or off via external logic. Burst-mode control manages the switch, and a bandwidth-select circuit using a high or low logic level input, wherein the laser is disabled and the bandwidth-select circuit enters a fast-track mode when the external logic signal has a first level. The laser provides regular optical signals, and the bandwidth-select circuit enters a slow-track mode, thereby enabling the APC loop to operate normally, when the external logic signal has a second level. In addition to a low cost and simple implementation, the control circuit and method provide lasers with a fast response capability using one or more externally-controlled switch circuits to meet demands of PON systems for burst-mode ONUs.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: April 26, 2016
    Assignee: Source Photonics (Chengdu) Co., Ltd.
    Inventors: Xu Jiang, Yuan Song, Shuyuan Zhang, Yuanzhong Xu
  • Patent number: 7888097
    Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
    Type: Grant
    Filed: October 29, 2007
    Date of Patent: February 15, 2011
    Assignee: Crucell Holland B.V.
    Inventors: Zheng Wu, Shuyuan Zhang
  • Patent number: 7888096
    Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
    Type: Grant
    Filed: June 26, 2007
    Date of Patent: February 15, 2011
    Assignee: Crucell Holland B.V.
    Inventors: Zheng Wu, Shuyuan Zhang
  • Patent number: 7732129
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Grant
    Filed: December 1, 1998
    Date of Patent: June 8, 2010
    Assignee: Crucell Holland B.V.
    Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
  • Publication number: 20100105124
    Abstract: The present invention relates to improved methods for producing adenovirus compositions wherein host cells are grown in a bioreactor and purified by size partitioning purification to provide purified adenovirus compositions.
    Type: Application
    Filed: October 28, 2009
    Publication date: April 29, 2010
    Inventors: Hai Pham, Shuyuan Zhang, Peter Clarke
  • Publication number: 20100055763
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Application
    Filed: October 2, 2009
    Publication date: March 4, 2010
    Inventors: SHUYUAN ZHANG, Capucine Thwin, Zheng Wu, Toohyon Cho
  • Publication number: 20090253184
    Abstract: Embodiments of the invention include E1 expressing cell lines that can be used in a variety of methods for production of an E1 defective adenovirus. In certain aspects a cell of the invention can be adapted to various culture conditions, e.g., suspension culture in serum free medium. In a further aspect, the cell lines allow isolation and subculture of E1-deleted recombinant adenoviruses in an environment free of replication competent adenovirus (RCA).
    Type: Application
    Filed: January 23, 2009
    Publication date: October 8, 2009
    Applicant: Introgen Therapeutics, Inc.
    Inventors: Peter Clarke, Shuyuan Zhang, Hai Pham, Joe Senesac
  • Patent number: 7510875
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: March 31, 2009
    Assignee: Introgen Therapuetics, Inc.
    Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah Wilson, Lucetta Caston
  • Publication number: 20080299182
    Abstract: Formulations of viral vectors for topical application are disclosed as well as methods for making the same. Also disclosed are methods of treating a subject or diagnosing disease in a subject using the formulations of the present invention.
    Type: Application
    Filed: February 29, 2008
    Publication date: December 4, 2008
    Inventors: Shuyuan Zhang, Eric Onishi
  • Publication number: 20080299545
    Abstract: Methods for determining the quantity, quality and purity of a previously purified virus sample are disclosed. Such methods, which include the use of high performance size exclusion chromatography to determine these attributes are also disclosed.
    Type: Application
    Filed: March 6, 2008
    Publication date: December 4, 2008
    Inventors: Shuyuan Zhang, Peter Clarke
  • Patent number: 7445930
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production witrh cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Grant
    Filed: July 30, 2004
    Date of Patent: November 4, 2008
    Assignee: Introgen Therapeutics Inc.
    Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Deborah Wilson, Lucetta Caston
  • Patent number: 7419808
    Abstract: The present invention addresses the need to improve the yield of adenovirus when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of infection temperatures lower than 37° C. in a cell culture system results in improved yields of adenovirus. In addition, it has been demonstrated that when host cells are grow in a bioreactor, initiating adenovirus infection by diluting the host cells with fresh media and adenovirus results in improved yield of adenovirus. Methods of adenoviral production and purification using infection temperatures less than 37° C. are disclosed. Methods of adenoviral production and purification wherein the host cells are grown in a bioreactor and adenovirus infection is initiated by diluting the host cells with fresh media and adenovirus are also disclosed.
    Type: Grant
    Filed: March 15, 2005
    Date of Patent: September 2, 2008
    Assignee: Introgen Therapeutics, Inc.
    Inventors: Shuyuan Zhang, Hai Pham
  • Publication number: 20080107631
    Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
    Type: Application
    Filed: June 26, 2007
    Publication date: May 8, 2008
    Applicant: Introgen Therapeutics, Inc.
    Inventors: Zheng Wu, Shuyuan Zhang
  • Publication number: 20080102508
    Abstract: The present invention addresses the need to improve the long-term storage stability (i.e. infectivity) of vector formulations. In particular, it has been demonstrated that for adenovirus, the use of bulking agents, cryoprotectants and lyoprotectants imparts desired properties that allow both lyophilized and liquid adenovirus formulations to be stored at 4° C. for up to 6 months and retain an infectivity between 60-100% of the starting infectivity.
    Type: Application
    Filed: October 29, 2007
    Publication date: May 1, 2008
    Applicant: Introgen Therapeutics, Inc.
    Inventors: Zheng Wu, Shuyuan Zhang
  • Publication number: 20080050770
    Abstract: The present invention addresses the need to improve the yields of viral vectors when grown in cell culture systems. In particular, it has been demonstrated that for adenovirus, the use of low-medium perfusion rates in an attached cell culture system provides for improved yields. In other embodiments, the inventors have shown that there is improved Ad-p53 production with cells grown in serum-free conditions, and in particular in serum-free suspension culture. Also important to the increase of yields is the use of detergent lysis. Combination of these aspects of the invention permits purification of virus by a single chromatography step that results in purified virus of the same quality as preparations from double CsCl banding using an ultracentrifuge.
    Type: Application
    Filed: August 24, 2006
    Publication date: February 28, 2008
    Applicant: Introgen Therapeutics, Inc.
    Inventors: Shuyuan Zhang, Capucine Thwin, Zheng Wu, Toohyon Cho, Shawn Gallagher
  • Publication number: 20080044378
    Abstract: The present invention provides methods and compositions for recombinant protein production through replication-defective adenoviral vector infection of non-trans-complementation cell lines. Thus, this invention describes methods of heterologous protein production without an accompanied production of adenoviral vectors.
    Type: Application
    Filed: May 15, 2007
    Publication date: February 21, 2008
    Applicant: INTROGEN THERAPEUTICS, INC.
    Inventors: Shuyuan Zhang, Hai Pham, Ping Song, Mingzhong Zheng, Peter Clarke
  • Publication number: 20070172846
    Abstract: The present invention relates to compositions comprising and methods for producing adenovirus compositions wherein host cells are grown in a bioreactor and purified by size partitioning purification to provide purified adenovirus compositions.
    Type: Application
    Filed: November 13, 2006
    Publication date: July 26, 2007
    Applicant: INTROGEN THERAPEUTICS, INC.
    Inventors: Shuyuan Zhang, Hai Pham, Ping Song, Peter Clarke
  • Patent number: D640140
    Type: Grant
    Filed: June 29, 2010
    Date of Patent: June 21, 2011
    Inventor: Shuyuan Zhang